Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.79
- Piotroski Score 3.00
- Grade Buy
- Symbol (WVE)
- Company Wave Life Sciences Ltd.
- Price $14.35
- Changes Percentage (0.63%)
- Change $0.09
- Day Low $13.89
- Day High $14.99
- Year High $16.74
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/27/2025
- Fiscal Year End N/A
- Average Stock Price Target $22.00
- High Stock Price Target $36.00
- Low Stock Price Target $15.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.51
- Trailing P/E Ratio -11.39
- Forward P/E Ratio -11.39
- P/E Growth -11.39
- Net Income $-57,513,000
Income Statement
Quarterly
Annual
Latest News of WVE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
WAVE Life Sciences Ltd (WVE) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...
Paul Bolno discusses the Huntington's program's anticipated costs and partnership structures, emphasizing open collaboration possibilities to reduce costs. Inhibin E aims to differentiate from GLP-1s ...
By Yahoo! Finance | 1 week ago -
Mountain West reprimands Wyoming coach Jay Sawvel for profane remarks about officiating
The Mountain West Conference reprimanded Wyoming coach Jay Sawvel for criticizing game officials after a loss to Utah State. Sawvel expressed regret for his behavior during a postgame news conference,...
By AP NEWS | 3 weeks ago -
Wave Life Sciences Ltd. (WVE) Stock Price, News, Quote & History
Stocks of RNA-editing companies surged following positive trial results showing promise for RNA-editing therapies. Wave Life Sciences Ltd. reported achieving significant results in a recent clinical t...
By Yahoo! Finance | 1 month ago
